This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

In animal experiments, it can prevent gastric relaxation, accelerate gastric motility, coordinate the movement of the antrum-duodenum, small intestine and large intestine; strengthen the digestive activity of the antrum-duodenum, coordinate and strengthen gastric emptying, increase the peristalsis of the small intestine and large intestine and shorten the intestinal movement time, but does not affect gastric secretion; it mainly exerts its effect by promoting the physiological release of acetylcholine in the myenteric plexus; it does not stimulate muscarinic and nicotinic receptors, nor does it inhibit the activity of acetylcholinesterase, and has no dopamine receptor blocking effect at therapeutic doses, and is mainly distributed in the stomach and intestinal tissues. In humans, it enhances esophageal motility and lower esophageal sphincter tension, prevents gastric contents from refluxing into the esophagus and improves esophageal clearance; increases gastric and duodenal contractility and antral-duodenal coordination, reduces duodenal-gastric reflux, and improves gastric and duodenal emptying; strengthens intestinal motility and promotes small and large intestine transit; lacks cholinergic effect, so it does not increase basal and pentagastrin-induced gastric acid secretion; relatively lacks dopamine antagonist properties and has almost no effect on plasma prolactin levels; does not affect psychomotor function, blood pressure, respiratory rate, body temperature, body weight and anticoagulation function; the pharmacological effect begins 30 to 60 minutes after oral administration.

1. Inhibits the redox reaction of amoeba, causing the nitrogen chain of the protozoa to break. 2. When the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all will be killed within 24 hours; when the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. 3. It has a strong effect of killing trichomonas, but the specific mechanism is unknown. 4. It has a killing effect on anaerobic microorganisms, and its metabolites also have anti-anaerobic effects, by inhibiting the synthesis of bacterial deoxyribonucleic acid, interfering with bacterial growth and reproduction, and ultimately causing bacterial death. It has a carcinogenic effect on some animals.

Extract from the above information